MetroGel 1% Hydration Study: A Kinetic Regression Study

NCT00436527 Phase 4 COMPLETED

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Details

Lead sponsor	Galderma R&D
Phase	Phase 4
Status	COMPLETED
Enrolment	26
Start date	2006-08
Completion	2006-08

Conditions

• Rosacea

Interventions

• Metronidazole gel 1%

Primary outcomes

• Six replicate Corneometer CM 825 measurements — 8 hours

Countries

United States